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tp://dx.doi.org/10.1016/j.hjc.2016
09-9666/ª 2016 Hellenic Cardiologi
ense (http://creativecommons.org/Anticoagulation therapy (AT) is the cornerstone of treat-
ment in atrial fibrillation (AF) for the prevention of possible
thromboembolic events. Until recently, vitamin K antago-
nists (VKAs) were the main class of oral drugs used in daily
clinical practice. New oral anticoagulants (NOACs) were a
revolution in the management of patients suffering from
non-valvular atrial fibrillation (NVAF).
Epidemiological data for AF in Greece is limited.1 This is
especially true for rural and remote areas. There is un-
certainty about the effectiveness and safety of NOACs in
unselected elderly patients in primary care.2 The purpose
of this study is to evaluate the anticoagulation therapy with
NVAF that was administered to patients in the remote and
rural areas of Sitia, Crete.
Our study was a single-center, 1-year prospective (from
January to December 2014), observational study that
enrolled consecutive patients with NVAF under anti-
coagulation or dual antiplatelet therapy (aspirin and clo-
pidogrel) from the emergency department or the
outpatient clinics of the Health Center e General Hospital
of Sitia in Crete. It was conducted in the area of the Mu-
nicipality of Sitia, which has a population of approximately
20,000 inhabitants. The study was performed according to
the ethical principles for medical research involving human
subjects specified in the Declaration of Helsinki. The study
protocol was designed by the Health Center of Sitia and
approved by the local ethics committee of our hospital.
The classification of AF as paroxysmal, persistent, or
permanent was performed according to the latest ESCof Hellenic Cardiological
.05.005
cal Society. Publishing services by
licenses/by-nc-nd/4.0/).guidelines for AF.3 In patients under therapy with VKAs, we
retrospectively recorded the international normalized ratio
(INR) values during the last six months prior to enrollment
in the study. The target therapeutic range of INR was 2e3.
Time in therapeutic range (TTR) was defined by two
commonly used methodologies. In the first method, TTR
was defined as the fraction of INRs the within target range
(Method A). In the second, we used the Rosendaal linear
interpolation of INR values4 (Method B). TTR 60% was
considered effective anticoagulation with VKA.
A total of 356 consecutive patients (172 men) were
enrolled in our study. The demographic and clinical char-
acteristics of the patients are shown in Table 1. The mean
CHA2DS2-VASc
3 and CHADS2 scores
3 for stroke risk were
4.631.54 and 3.001.27, respectively, while the mean
HAS-BLED score3 was 3.001.05.
Ninety-six percent of patients with NVAF were treated
with anticoagulant agents (Fig. 1). Four percent of patients
received dual antiplatelet therapy. Acenocoumarol was the
only VKA agent recorded in our region. Nineteen patients
had changed the anticoagulation therapy from VKA to a
NOAC. The reasons for this change of AT were unstable INR
(8 patients), the occurrence of hemorrhagic stroke (6 pa-
tients), distance from the health care unit (3 patients) and
food preferences of the patient (2 patients). Sixty-six
percent of patients had regular follow-up of the
arrhythmia (at least once a year), while 28% of patients had
not revisited a cardiologist after the initial diagnosis of the
arrhythmia.
Overall, 63.1% of patients treated with VKAs had regular
measurements of INR on a monthly basis, while 2.6% of
patients at the time of the enrollment were unaware of the
need to measure the INR during treatment with VKAs.
Appropriate data for the TTR analysis were available for
135 patients on VKA treatment. The mean TTR for all pa-
tients in our study was 43.72% and 52.36% with methods A
and B, respectively. A TTR 60% was observed in 30.4% of
patients with method A and in 38.5% of patients with B
method.
The study of rural and remote areas is interesting and
challenging, as these regions usually have special cultural
conditions in combination with limited access to healthcareElsevier B.V. This is an open access article under the CC BY-NC-ND
Table 1 Baseline demographic and clinical characteristics
of patients.
nZ356 (100%) Mean  SD
Age 356 (100%) 78.47  9.1
Men 172 (48.3%)
Hypertension 317 (89%)
Smokers 142 (39.9%)
Active smokers 38 (10.7%)
Ex-smokers 104 (29.2%)
Dyslipidemia 178 (50%)
Diabetes Mellitus 121 (34%)
Coronary artery disease 50 (14%)
Heart failure 221 (62%)
NYHA I 43 (12%)
NYHA II 144 (40.4%)
NYHA III 28 (7.9%)
NYHA IV 6 (1.7%)
History of TIA / stroke* 82 (23%)
AF type
Paroxysmal AF 117 (32.9%)
Persistent AF 25 (7%)
Permanent AF 214 (60.1%)
Other Cardiac Medications heart**
B-blockers 183 (51.4%)
Diltiazem 16 (4.5%)
Digoxin 15 (4.2%)
Propafenone 22 (6.2%)
Amiodarone 43 (12.1%)
Sotalol 5 (1.4%)
NYHA: New York Heart Association; TIA: Transient ischemic
attack; AF: Atrial fibrillation
* The TIA / stroke was the initial manifestation of AF for 35
patients.
** Other cardiac medications include only drugs for controlling
heart rate or heart rhythm
Figure 1 Anticoagulation drug therapy in study population.
The percentages (%) are in reference to the total population of
the study (356 patients). OAC: Oral anticoagulant; NOAC: New
Oral Anticoagulant; VKA: Vitamin K antagonist; BID: bis in die;
QD: quaque die.
280 Letter to the Editorservices. RAFTING5 and MANAGE-AF1 are the two largest
and most representative studies of the Greek population
available for the treatment of AF at the national level. The
MANAGE-AF1 is the only Greek multi-center national regis-
try to record the use of NOACs in AF. However, in this study
only one NOAC (dabigatran) was included. To the best of
our knowledge, ours is the first study concerning the anti-
coagulation management of NVAF in a rural and remote
area of Greece where the three new available oral anti-
coagulant agents (dabigatran, rivaroxaban, apixaban) were
available.
In our registry, dabigatran at a reduced dose (110 mg
BID) ranked first among the NOACs. Not surprisingly, the
above data were expected, as dabigatran was the first
NOAC approved for the treatment of NVAF. Until recently, it
was not available in Greece at a dose of 150 mg. Edoxaban
was not available in Greece during the registration period
of the study.
Some of the most recent data in the literature con-
cerning the use of NOACs in AF were recorded in the
American PINNACLE-AF registry6 for a total of 150,000 pa-
tients. In this study, NOACs were used in 13% of AF patients
in 2011. However, the PREFER7 and EORP-AF198 studies
recorded a smaller percentage of patients receiving NOACs
(6.1% and 8.4% of patients, respectively). In the GARFIELD
registry,9 increased use of NOACs was observed over time,
with a reduction in the use of VKAs.
The average TTR observed in participating Greek pa-
tients in the RE-LY10 study was 56%. In MANAGE-AF,1 the TTR
of patients was not calculated, but indirect conclusions can
be derived from the baseline mean INR value in the study
population, which was 1.70.8. In our study, the majority
of patients had TTR <60%, which shows poor adherence to
treatment with VKAs.
In conclusion, most of the patients in our study were
under treatment with VKAs, which require strict control to
maintain the INR values in the therapeutic range. Possible
reasons why this problem is not remedied by converting to
NOACs may be either the reluctance of doctors to prescribe
them or the unwillingness of patients in previously estab-
lished therapy with VKA to convert to newer treatments.
Another important factor, especially in a country in eco-
nomic crisis such as Greece, is the high cost of NOACs. In
our view, we believe that the establishment of national
guidelines, especially in a country like Greece with its
unique characteristics, will lead to a gradual harmonization
of clinical practice in primary care with current European
recommendations.
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